Posts Tagged ‘Pharma’

Anthony LaFauce
Anthony
LaFauce

Digital Pharma East: I Got iPad Fever

Thursday, October 20th, 2011

I know the title of this blog post may seem a little odd. What is iPad fever? Can I catch it? What are the symptoms? Who is to blame?

Don’t worry there is an easy way to pinpoint if you might have a problem:

  • Does your CEO get doe-eyed when they see an iPad?
  • Do your fellow colleagues carry around iPads like they are small children?
  • Does “Let’s make an app!” come up in almost every brainstorm?
  • Does your company think the iPad will solve all of your marketing needs?

If you answered yes to any of these questions you might have iPad fever.

(more…)

Posted in Crowdsourcing, Digital Pharma East, Innovation, New Media, PR Industry, Social Media, Technology
By | Comments Off

Tags: , , ,

 
Anthony LaFauce
Anthony
LaFauce

Digital Pharma East 2011 Day One

Tuesday, October 18th, 2011

A big thank you is in order to my employer, Spectrum, as I attend Digital Pharma East this week. Day one kicked off with a great session lead by Takeda Pharmaceuticals Chad Ballentine who spoke about how to use a patient focused, multi-channel, customer relationship management (CRM) to really capitalize on your database to assure you are getting the right information to the right people…and of course increase sales.

Chad had a ton of good points but I was blown away by his simple, and spot on, key points on how to get the best value out of your CRM.

  1. Use digital [technology] to grow your database
  2. Use your database: Chad said that nearly 60 percent of marketers don’t actually use their DB
  3. Minimze duplication: With budgets scalling down, efficiency is key. If you have a high conversion touch point, make sure to increase your efforts toward that touch point and scale back those that don’t work well

Social Media & Pharma…it’s out there

As I sit here and type, drinking my coffee, Todd Kolm from Pfizer is on the stage talking about some of the great tools Pfizer is using to engage customers. Pfizer is taking to social media and positioning YouTube as an educational tool for consumers by using a blend of paid ads and search ads which link to channels with custom play lists.

As a lover of PR/Digital media I am constantly getting hit with, “oh Pharma doesn’t really do social” or “we don’t want to deal with the legal issues.” I am surrounded by around 700 people who see things differently. I am energized by hearing not what we COULD do but hearing about what we ARE doing.

Anyone else out there excited about this?

Posted in Digital Pharma East, Health 2.0, Health Care Industry, Innovation, New Media, Pharma, PR Industry, Public Health, Social Media, Technology
By | Comments Off

Tags: , , , ,

 
jseng
John
Seng

In Memoriam: Dr. Bruce Dan, Medical Newsmaker and Friend

Monday, September 12th, 2011

This past Tuesday evening, my friend Bruce Dan passed away after a lengthy battle with acute myelogenous leukemia (AML), a fairly rare blood and bone marrow cancer. He had been receiving treatment at Johns Hopkins over the past year-and-a-half. During this last journey, he persisted in his passion: story-telling in health care. Except this time, he was the subject. I was introduced to Dr. Bruce B. Dan in the mid-1990s by another friend and former boss, Ken Rabin.

At the time, Ken knew Bruce to be an outstanding media trainer, and it was Bruce’s unique brand of health care media counseling skills that I relied upon over a stretch of more than 15 years. For real “heavy lifting,” in other words, when we figured we would need a double shot of TLC to render articulate the driest medical expert or bombastic pharmaceutical company executive, we called in Bruce.

During any session, Bruce kicked things off with his characteristic big smile, and quiet, engaging style that within minutes put everyone in the room at ease. The man would roll onward, keeping one step ahead with anecdotes, witticisms or piercing questions as he led captive audiences through his training sessions, usually flanked by a medium-sized stack of VHS tapes he used to depict horrific and then good examples of television interview behavior. (Clients always got to keep their own tapes.)

Anytime I called on Bruce, I always tried to carve out extra time with him, to learn from his experiences and get his feedback on my business situations or ideas. Bruce was generous.

Not only did he sincerely care about your point of view, and in his patient style give you all the time you needed, he demonstrated the very best in teaching skills: You learned without even realizing it, Bruce was knowledgeable, interesting and persuasive.

(more…)

Posted in Awards, Cancer
By | 2 Comments »

Tags: , , ,

 
Anthony LaFauce
Anthony
LaFauce

What does Google’s Fine Mean for Your PPC?

Wednesday, August 24th, 2011

Today or tomorrow the Department of Justice is expected to announce Google will have to pay half a billion dollars in fines for ads run on its network that sold illegal drugs.  For the better part of a year, Google had been battling with online  ’pharmacies’ about the products they sell.

Google had stated in official documents, due to the difficult nature of regulating ads on their network they shouldn’t be held accountable for ads they were actively removing.  Google’s official statement, “… it’s obvious with hindsight that we shouldn’t have allowed these ads on Google in the first place. Given the extensive coverage this settlement has already received, we won’t be commenting further,” is clear and concise. They messed up and they know it.

(more…)

Posted in Congress, Health 2.0, mobile, New Media, Pharma, Social Media, Technology
By | Comments Off

Tags: , , , , ,

 
KellyBarrett
Kelly
Barrett

BDI’s Social Communications & Healthcare 2011: Empowering employees to ‘play’ with social media

Tuesday, July 19th, 2011

Last Wednesday, I had the pleasure of attending the Business Development Institute’s Social Communications & Healthcare conference in New York City. It was the third year that BDI has put on the conference but one of the first times the event has included such robust case studies from industry leaders.

It is unfortunate that in pharma, we really don’t have many social media case studies to look at, yet. And this isn’t just because social media is new, because really, it’s not that new anymore (and what’s new today is old tomorrow). The problem lies more in the fact that so many companies and agencies are doing innovative stuff that they aren’t yet allowed to disclose. Here at Spectrum, a number of our progressive social media-related initiatives are highly sensitive and stay confidential. However, in the meantime, it’s inspiring to see all the ways people are finding to best socially communicate.

BDI Wrap Up from Zemoga on Vimeo.

(Pixels & Pills covered the event and they provide a ton of great video interviews that you should check out. And New Millenium Research & Consulting has photos up on their Facebook.)

(more…)

Posted in Biotechnology, Blogosphere, Community Involvement, Crowdsourcing, doctors, PR Industry, Research, Social Media, Technology
By | Comments Off

Tags: , , , , , , ,

 
HSilverman
Harold
Silverman

Top 5 Challenges of Biosimilars

Tuesday, October 26th, 2010

syringe_glove_01The Food and Drug Administration is wrestling with how to best implement the Biologics Price Competition and Innovation Act. The agency is writing regulations that will set the exact rules for gaining biosimilar approval and has scheduled a meeting to obtain public input on the regulatory pathway that is being considered. The meeting is set for November 2-3 and will be held at FDA’s facility in Silver Spring, Maryland. The full meeting announcement can be found here. A live webcast of the 2-day event can be found here.

A quick look at some of the issues the FDA wants input on during the hearing shows how different biosimilars are from traditional generic regulation. Besides those discussed below, the FDA is seeking comment on a variety of marketing, technical and regulatory issues. The breadth and depth of all these questions speak to the complexities of the issues that are being dealt with. Given the uncertainty surrounding pending decisions and their impact on companies seeking to enter the biosimilar market, I believe the first U.S. biosimilar will not to be approved for at least two years.

(more…)

Posted in Biotechnology, Health Care Industry, Research
By | Comments Off

Tags: , ,

 
« Older Entries